PB2080: EFFICACY AND SAFETY OF BENDAMUSTINE-BASED REGIMENS AS FIRST-LINE TREATMENT FOR INDOLENT B-CELL NON-HODGKIN LYMPHOMA: A PROSPECTIVE, MULTICENTER, REAL-WORLD STUDY IN CHINA

• S. Li,
• S.-J. Wen,
• J. Ma

Affiliations

S. Li

1 Department of Lymphoma, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi

S.-J. Wen

1 Department of Lymphoma, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi

J. Ma

2 Department of Hematology & Oncology, Harbin Institute of Hematology & Oncology, Harbin, China